Risk factors for COVID-19 case fatality rate in people with type 1 and type 2 diabetes mellitus: A nationwide retrospective cohort study of 235,248 patients in the Russian Federation
Shestakova et al.,
Risk factors for COVID-19 case fatality rate in people with type 1 and type 2 diabetes mellitus: A nationwide..,
Frontiers in Endocrinology, doi:10.3389/fendo.2022.909874
Retrospective 224,190 type 2 diabetes patients in Russia, showing lower mortality with metformin use.
risk of death, 21.6% lower, RR 0.78, p = 0.001, treatment 21,471 of 139,637 (15.4%), control 12,721 of 50,361 (25.3%), adjusted per study, odds ratio converted to relative risk, Table S2, multivariable.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Shestakova et al., 9 Aug 2022, retrospective, Russia, peer-reviewed, 6 authors, study period 20 March, 2020 - 25 November, 2021.
Contact:
olga-vikulova-1973@yandex.ru.
Abstract: TYPE Original Research
PUBLISHED 09 August 2022
DOI 10.3389/fendo.2022.909874
OPEN ACCESS
EDITED BY
Fariba Ahmadizar,
University Medical Center Utrecht,
Netherlands
REVIEWED BY
Anu Grover,
Ipca Laboratories, India
Sergi Trias-Llimós,
Autonomous University of Barcelona,
Spain
Vadim Klimontov,
Russian Academy of Sciences (RAS),
Russia
*CORRESPONDENCE
O. K. Vikulova
olga-vikulova-1973@yandex.ru
Risk factors for COVID-19 case
fatality rate in people with type
1 and type 2 diabetes mellitus: A
nationwide retrospective cohort
study of 235,248 patients in the
Russian Federation
M. V. Shestakova, O. K. Vikulova *, A. R. Elfimova, A.
A. Deviatkin, I. I. Dedov and N. G. Mokrysheva
Endocrinology Research Centre, Moscow, Russia
SPECIALTY SECTION
This article was submitted to
Clinical Diabetes,
a section of the journal
Frontiers in Endocrinology
RECEIVED 31 March 2022
ACCEPTED 28 June 2022
PUBLISHED 09 August 2022
The aim: To study the association of demographic, clinical, and laboratory
factors and the use of glucose-lowering drugs and anti-coronavirus disease
(COVID-19) vaccination with the COVID-19-related case fatality rate (CFR) in
diabetes mellitus (DM) patients.
CITATION
Shestakova MV, Vikulova OK,
Elfimova AR, Deviatkin AA, Dedov II
and Mokrysheva NG (2022) Risk
factors for COVID-19 case fatality rate
in people with type 1 and type 2
diabetes mellitus: A nationwide
retrospective cohort study of 235,248
patients in the Russian Federation.
Front. Endocrinol. 13:909874.
doi: 10.3389/fendo.2022.909874
COPYRIGHT
© 2022 Shestakova, Vikulova, Elfimova,
Deviatkin, Dedov and Mokrysheva. This
is an open-access article distributed
under the terms of the Creative
Commons Attribution License (CC BY).
The use, distribution or reproduction
in other forums is permitted, provided
the original author(s) and the
copyright owner(s) are credited and
that the original publication in this
journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is
permitted which does not comply with
these terms.
Frontiers in Endocrinology
Methods: This study is a nationwide observational cohort study based on the
data from the National Diabetes Register (NDR) that is the database containing
online clinical information about the population with DM. The outcomes (death
or recovery) for COVID-19 were registered in 235,248 patients with DM [type 1
diabetes mellitus (T1DM), n = 11,058; type 2 diabetes mellitus (T2DM), n =
224,190] from March 20, 2020, until November 25, 2021. The unadjusted odds
ratio (OR) and 95% confidence interval (CI) were used to estimate the risk
factors for CFR. Then the ranging of significant factors was performed and the
most vulnerable groups of factors for the lethal outcome were chosen.
Results: The CFR due to COVID-19 was 8.1% in T1DM and 15.3% in T2DM.
Increased CFR was associated with the male population [OR = 1.25 (95% CI:
1.09–1.44) in T1DM and 1.18 (95% CI: 1.15–1.21) in T2DM], age ≥65 years [OR =
4.44 (95% CI: 3.75–5.24) in T1DM and 3.18 (95% CI: 3.09–3.26) in T2DM], DM
duration ≥10 years [OR = 2.46 (95% CI: 2.06–2.95) in T1DM and 2.11 (95% CI:
2.06–2.16) in T2DM], body mass index (BMI) ≥30 kg/m2 [OR = 1.95 (95% CI:
1.52–2.50)] in T1DM, HbA1c ≥7% [OR = 1.35 (95% CI: 1.29–1.43)] in T2DM. The
atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease
(CKD) were associated with higher CFR in T1DM but not in T2DM. The preCOVID-19 glucose-lowering therapy in T2DM was differently..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit